The University of Southampton
University of Southampton Institutional Repository
Warning ePrints Soton is experiencing an issue with some file downloads not being available. We are working hard to fix this. Please bear with us.

Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension

Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension
Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension

The TOMORROW trial of nintedanib comprised a randomised, placebo-controlled, 52-week period followed by a further blinded treatment period and an open-label extension. We assessed outcomes across these periods in patients randomised to nintedanib 150 mg twice daily or placebo at the start of TOMORROW. The annual rate of decline in FVC was -125.4 mL/year (95% CI -168.1 to -82.7) in the nintedanib group and -189.7 mL/year (95% CI -229.8 to -149.6) in the comparator group. The adverse event profile of nintedanib remained consistent throughout the studies. These results support a benefit of nintedanib on slowing progression of idiopathic pulmonary fibrosis beyond 52 weeks.

Idiopathic pulmonary fibrosis
0040-6376
581-583
Richeldi, Luca
47177d9c-731a-49a1-9cc6-4ac8f6bbbf26
Kreuter, Michael
f97455b8-d063-4e97-b0d2-c8bc715d04a2
Selman, Moisés
42c44609-778c-4180-9ffc-fa913a68fbf8
Crestani, Bruno
865ae575-7955-4d9d-a3b9-c1c41e53e935
Kirsten, Anne Marie
0237e4b0-2062-4d05-a7bc-38d5b2f7f550
Wuyts, Wim A.
ce2b522f-eb3d-46e8-9209-06036e3c43a4
Xu, Zuojun
84d35664-524f-4301-a642-a8fa05c5ce4c
Bernois, Katell
83d5c376-dbb9-4c95-970d-ff8affe85a09
Stowasser, Susanne
db03e3f9-5df8-403d-b6f7-5284a506fd94
Quaresma, Manuel
8dc51c06-a7a5-46e9-9da1-ff3d4b78128f
Costabel, Ulrich
4dc38723-49b2-4f71-aeee-6b959553c3b8
Richeldi, Luca
47177d9c-731a-49a1-9cc6-4ac8f6bbbf26
Kreuter, Michael
f97455b8-d063-4e97-b0d2-c8bc715d04a2
Selman, Moisés
42c44609-778c-4180-9ffc-fa913a68fbf8
Crestani, Bruno
865ae575-7955-4d9d-a3b9-c1c41e53e935
Kirsten, Anne Marie
0237e4b0-2062-4d05-a7bc-38d5b2f7f550
Wuyts, Wim A.
ce2b522f-eb3d-46e8-9209-06036e3c43a4
Xu, Zuojun
84d35664-524f-4301-a642-a8fa05c5ce4c
Bernois, Katell
83d5c376-dbb9-4c95-970d-ff8affe85a09
Stowasser, Susanne
db03e3f9-5df8-403d-b6f7-5284a506fd94
Quaresma, Manuel
8dc51c06-a7a5-46e9-9da1-ff3d4b78128f
Costabel, Ulrich
4dc38723-49b2-4f71-aeee-6b959553c3b8

Richeldi, Luca, Kreuter, Michael, Selman, Moisés, Crestani, Bruno, Kirsten, Anne Marie, Wuyts, Wim A., Xu, Zuojun, Bernois, Katell, Stowasser, Susanne, Quaresma, Manuel and Costabel, Ulrich (2018) Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension. Thorax, 73 (6), 581-583. (doi:10.1136/thoraxjnl-2016-209701).

Record type: Article

Abstract

The TOMORROW trial of nintedanib comprised a randomised, placebo-controlled, 52-week period followed by a further blinded treatment period and an open-label extension. We assessed outcomes across these periods in patients randomised to nintedanib 150 mg twice daily or placebo at the start of TOMORROW. The annual rate of decline in FVC was -125.4 mL/year (95% CI -168.1 to -82.7) in the nintedanib group and -189.7 mL/year (95% CI -229.8 to -149.6) in the comparator group. The adverse event profile of nintedanib remained consistent throughout the studies. These results support a benefit of nintedanib on slowing progression of idiopathic pulmonary fibrosis beyond 52 weeks.

This record has no associated files available for download.

More information

Accepted/In Press date: 31 July 2017
e-pub ahead of print date: 9 October 2017
Published date: 1 June 2018
Keywords: Idiopathic pulmonary fibrosis

Identifiers

Local EPrints ID: 424719
URI: http://eprints.soton.ac.uk/id/eprint/424719
ISSN: 0040-6376
PURE UUID: faa46dca-dbd9-4982-ad31-eeae836f40ba

Catalogue record

Date deposited: 05 Oct 2018 11:41
Last modified: 25 Nov 2021 18:52

Export record

Altmetrics

Contributors

Author: Luca Richeldi
Author: Michael Kreuter
Author: Moisés Selman
Author: Bruno Crestani
Author: Anne Marie Kirsten
Author: Wim A. Wuyts
Author: Zuojun Xu
Author: Katell Bernois
Author: Susanne Stowasser
Author: Manuel Quaresma
Author: Ulrich Costabel

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×